Aridis Pharmaceuticals Inc expected to post a loss of 51  cents a share - Earnings Preview

Aridis Pharmaceuticals

06/05/2022 13:41

* Aridis Pharmaceuticals Inc  ARDS.OQ   ARDS.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 9 (estimated). 
    * The Los Gatos California-based  company is expected to
report
revenue of $2 million, according to the estimate from one
analyst, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Aridis
Pharmaceuticals
Inc is for a loss of 51 cents per share. For the same quarter
last year, the company reported a loss of 77 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $14​, above​ its last closing price
of $1.18. ​​​

This summary was machine generated May 6 at 12:41 GMT.  All
figures in US dollars  unless otherwise stated